Chapin Davis Inc. Takes Position in LivaNova PLC (NASDAQ:LIVN)

Chapin Davis Inc. purchased a new position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 17,000 shares of the company's stock, valued at approximately $668,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Freestone Grove Partners LP acquired a new position in shares of LivaNova during the 4th quarter worth approximately $23,102,000. Artisan Partners Limited Partnership acquired a new stake in LivaNova during the fourth quarter worth approximately $21,340,000. The Manufacturers Life Insurance Company grew its position in LivaNova by 163.6% during the fourth quarter. The Manufacturers Life Insurance Company now owns 546,387 shares of the company's stock worth $25,303,000 after buying an additional 339,139 shares in the last quarter. AQR Capital Management LLC increased its stake in LivaNova by 79.3% during the 4th quarter. AQR Capital Management LLC now owns 742,180 shares of the company's stock worth $34,214,000 after acquiring an additional 328,313 shares during the period. Finally, Vanguard Group Inc. raised its holdings in LivaNova by 12.7% in the 4th quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock valued at $108,823,000 after acquiring an additional 265,291 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

LivaNova Price Performance

LIVN stock opened at $45.51 on Monday. LivaNova PLC has a 1 year low of $32.48 and a 1 year high of $57.35. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.58 and a quick ratio of 1.37. The stock has a market cap of $2.48 billion, a price-to-earnings ratio of -11.13 and a beta of 0.90. The company has a 50 day simple moving average of $41.63 and a 200 day simple moving average of $43.57.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. The Goldman Sachs Group cut their target price on LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Wolfe Research raised shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective for the company in a research report on Tuesday, May 20th. Robert W. Baird increased their price objective on shares of LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. Barclays dropped their target price on shares of LivaNova from $56.00 to $55.00 and set an "equal weight" rating for the company in a research report on Thursday, May 8th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $64.00 price target on shares of LivaNova in a report on Tuesday, May 13th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $59.29.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.